Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

112 results about "Transferrin receptor" patented technology

Transferrin receptor (TfR) is a carrier protein for transferrin. It is needed for the import of iron into the cell and is regulated in response to intracellular iron concentration. It imports iron by internalizing the transferrin-iron complex through receptor-mediated endocytosis. The existence of a receptor for transferrin iron uptake had been recognized over half a century back. Earlier two transferrin receptors in humans, transferrin receptor 1 and transferrin receptor 2 had been characterized and until recently cellular iron uptake was believed to occur chiefly via these two well documented transferrin receptors. Both these receptors are transmembrane glycoproteins. TfR1 is a high affinity ubiquitously expressed receptor while expression of TfR2 is restricted to certain cell types and is unaffected by intracellular iron concentrations. TfR2 binds to transferrin with a 25-30 fold lower affinity than TfR1. Although TfR1 mediated iron uptake is the major pathway for iron acquisition by most cells and especially developing erythrocytes, several studies have indicated that the uptake mechanism varies depending upon the cell type. It is also reported that Tf uptake exists independent of these TfRs although the mechanisms are not well characterized. The multifunctional glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH,EC 1.2.1.12) has been shown to utilize post translational modifications to exhibit higher order moonlighting behavior wherein it switches its function as a holo or apo transferrin receptor leading to either iron delivery or iron export respectively.

Blood-brain barrier crossing antibodies

The present invention relates to antibodies or antibody fragments that bind to human and non-human primate transferrin receptors. The antibodies described herein can be used as agents to deliver pharmaceutical compounds into or through cells during receptor-mediated endocytosis and / or transendocytosis processes. As transferrin receptors are also present in the blood brain barrier endothelial cells, one aspect of the invention provides means and methods to increase delivery of pharmaceutical compounds to the central nervous system.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +1

Bipeptide modified bionic nano-vesicle as well as preparation method and application thereof

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV

PH-responsive drug self-delivery nano system as well as preparation method and application thereof

The invention relates to the technical field of medical nano-materials, and discloses a pH-responsive drug self-delivery nano-system and a preparation method and application thereof.The preparation method comprises the steps that 1, CMNPs is prepared, specifically, through an amidation reaction, the CMNPs are prepared from methotrexate and cis-aconitic anhydride; step 2, synthesizing DSPE-PEG-T12: synthesizing the DSPE-PEG-T12 by virtue of a nucleophilic addition reaction; step 3, preparing a T12 peptide modified erythrocyte membrane; and step 4, preparing T12-RBCM (at) CMNPs: modifying the T12 peptide of the targeted tumor cell transferrin receptor on an erythrocyte membrane, and coating the CMNPs to construct the nano-acquisition system T12-RBCM (at) CMNPs. According to the nano system T12-RBCM (at) CMNPs obtained by the scheme, the tumor cell uptake efficiency can be remarkably improved, cell apoptosis is induced, and proliferation is inhibited; the long-acting circulation and tumor targeting capability is realized, the tumor growth can be effectively inhibited, and the biological safety is good.
Owner:STOMATOLOGICAL HOSPITAL OF CHONGQING MEDICAL UNIV

Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Disclosed herein are antibody oligonucleotide conjugates and pharmaceutical compositions that induce an alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping. Also described herein include methods for treating muscle dystrophy including Duchenne muscular dystrophy that comprises administering antibody oligonucleotide conjugates or a pharmaceutical composition that induces alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping.
Owner:AVIDITY BIOSCI INC

Multispecific antibodies

The present invention relates to a multispecific antibody for transporting a compound across the blood brain barrier (BBB), wherein the antibody binds to at least two target proteins selected from the group consisting of the transferrin receptor (TFRC), CD98 (SLC3A2) and PODXL.
Owner:F HOFFMANN LA ROCHE & CO AG

Single-chain donanemab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of donanemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Receptor-mediated endocytosis for targeted internalization of c-c chemokine receptor 6

PCT designated stageWO2026142988A1IntracellularReceptor-mediated endocytosis
Disclosed are compositions that can bind to a CCR6 G Protein-Coupled Receptor (GPCR) and to a transferrin receptor on a cell surface. Once bound, the protein of interest (CCR6) can be internalized and / or degraded inside a cell.
Owner:DANA FARBER CANCER INSTITUTE INC

Single-chain natalizumab antibody-transferrin fusion protein for enhanced efficacy and indications

PendingUS20260049147A1Hybrid immunoglobulinsTransferrinsNatalizumab AntibodyExocytosis
The efficacy and indication of natalizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single chain adalimumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of adalimumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors
Owner:RNA THERAPEUTICS INC

Single-chain ranibizumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of ranibizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain alemtuzumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of ALEMTUZUMAB do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Owner:DYNE THERAPEUTICS INC

Single-chain MEDI1341 antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of MEDI1341 do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Transferrin coating agents for Alzheimer's disease relief therapy

The invention discloses a transferrin coating agent for relieving and treating Alzheimer's disease, and belongs to the technical field of biological medicine. The transferrin coating agent is prepared from transferrin-curcumin nanoparticles and a dispersion medium, the transferrin-curcumin nanoparticle comprises curcumin and transferrin, wherein the curcumin is directly wrapped in a hydrophobic cavity of the transferrin through hydrophobic interaction; the dispersion medium is a phosphate buffer solution containing ethanol by volume. The loading mode of the curcumin enables the hydrophobic curcumin to be coated in a hydrophilic carrier, so that the water solubility and the stability in blood circulation of the curcumin are remarkably improved, and metabolic clearance is slowed down; meanwhile, efficient and selective intracerebral delivery of curcumin is realized through a receptor-mediated endocytosis transport mechanism by virtue of specific binding of transferrin and a transferrin receptor on a blood brain barrier endothelial cell.
Owner:ANHUI AGRICULTURAL UNIVERSITY +1

Lipid nanoparticles for delivery to the CNS from systemic administration

The present disclosure relates to LNP formulations useful for uptake in the CNS or brain, for example, in some cases wherein the LNP is conjugated to an antigen binding fragment of an anti-transferrin receptor antibody. The present disclosure also relates to methods of delivering lipid nanoparticles (LNPs) systemically, for uptake in vivo in the central nervous system (CNS), such as to brain cells, and methods for assessment of the extent of uptake in CNS cells, such as brain cells. In some cases, methods allow for high throughput screening of multiple different LNPs in parallel.
Owner:GENENTECH INC

Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Disclosed herein are antibody oligonucleotide conjugates and pharmaceutical compositions that induce an alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping. Also described herein include methods for treating muscle dystrophy including Duchenne muscular dystrophy that comprises administering antibody oligonucleotide conjugates or a pharmaceutical composition that induces alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping.
Owner:AVIDITY BIOSCI INC

Single-chain dupilumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of dupilumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain solanezumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of solanezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain prasinezumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of prasinezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain semorinemab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of semorinemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain cetuximab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of cetuximab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain tildrakizumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of tildrakizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Antagonistic peptides of gdf15 and uses thereof

PendingCN122277661ABiological validationPharmaceutical Substances
This invention belongs to the field of biomedical technology, specifically relating to a GDF15 antagonistic peptide and its application. The amino acid sequence of the antagonistic peptide is shown in SEQ ID NO.1. To improve drug stability and blood-brain barrier penetration, GDF15-A-Pep was fused with albumin and transferrin receptor nanobodies. Biological validation results showed that the fusion protein significantly inhibited GDF15-induced MMP1 transcription and protein expression, and exhibited potent antagonistic activity in reporter gene experiments. This invention not only reveals the key structural basis of GDF15 receptor recognition but also provides experimental evidence for the development of novel GDF15 antagonistic drugs with central regulatory potential.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Single-chain gantenerumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of gantenerumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Bispecific binding molecule

PCT designated stageWO2026068532A1Nervous disorderAntibody ingredientsAmyloid betaTransferrin receptor
The present disclosure provides a bispecific binding molecule, which binds to protofibrils of amyloid beta and to the protease-like domain of human transferrin receptor 1 (hTfR1), as well as therapeutic and diagnostic uses thereof.
Owner:BIOARCTIC AB

Nucleic acids for inhibiting expression of transferrin receptor 2

Provided herein are nucleic acids and compositions thereof for inhibiting expression of transferrin receptor 2 (TFR2). Also described are methods for treatment of TFR2-associated diseases, such as anemia, with the disclosed nucleic acids.
Owner:DEXCEL PHARMA TECH LTD

VHH antibodies and uses thereof

The present invention relates to variable domain of heavy chain-only (VHH) antibody binding specifically to the transferrin receptor 1 (TfR1) and uses thereof to transport therapeutic agents or imaging agents into cells and over the blood-brain barrier.
Owner:KEY2BRAIN AB